+

WO2000033869A3 - Nouveaux traitements contre le cancer - Google Patents

Nouveaux traitements contre le cancer Download PDF

Info

Publication number
WO2000033869A3
WO2000033869A3 PCT/GB1999/004129 GB9904129W WO0033869A3 WO 2000033869 A3 WO2000033869 A3 WO 2000033869A3 GB 9904129 W GB9904129 W GB 9904129W WO 0033869 A3 WO0033869 A3 WO 0033869A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cancer
tumour
cell
taas
Prior art date
Application number
PCT/GB1999/004129
Other languages
English (en)
Other versions
WO2000033869A2 (fr
Inventor
Angus George Dalgleish
Peter Michael Smith
Andrew Derek Sutton
Anthony Ian Walker
Original Assignee
Onyvax Ltd
Angus George Dalgleish
Peter Michael Smith
Andrew Derek Sutton
Anthony Ian Walker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000586359A priority Critical patent/JP4949554B2/ja
Priority to MXPA01005816A priority patent/MXPA01005816A/es
Priority to AT99959542T priority patent/ATE304365T1/de
Priority to HU0104568A priority patent/HUP0104568A3/hu
Priority to EP99959542A priority patent/EP1137422B1/fr
Priority to AU16683/00A priority patent/AU763485B2/en
Priority to US09/857,691 priority patent/US6972128B1/en
Priority to NZ512004A priority patent/NZ512004A/en
Priority to IL14329699A priority patent/IL143296A0/xx
Application filed by Onyvax Ltd, Angus George Dalgleish, Peter Michael Smith, Andrew Derek Sutton, Anthony Ian Walker filed Critical Onyvax Ltd
Priority to DE69927286T priority patent/DE69927286T2/de
Priority to KR1020017007096A priority patent/KR20010090874A/ko
Priority to CA2354045A priority patent/CA2354045C/fr
Publication of WO2000033869A2 publication Critical patent/WO2000033869A2/fr
Publication of WO2000033869A3 publication Critical patent/WO2000033869A3/fr
Priority to IL143296A priority patent/IL143296A/en
Priority to NO20012634A priority patent/NO327044B1/no
Priority to US11/178,415 priority patent/US8034360B2/en
Priority to US13/270,820 priority patent/US20120164099A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un produit comportant une ou plusieurs lignées cellulaires utilisées comme agent d'immunothérapie allogénique pour le traitement du cancer -hez les mammifères et les êtres humains. A ce jour, toutes les études portant sur les vaccins contre le cancer basés sur un traitement cellulaire ont une caractéristique commune, plus précisément l'intention d'utiliser les cellules contenant au moins certains antigènes spécifiques de tumeur et/ou antigènes associés aux tumeurs qui sont partagés avec les antigènes présents dans la tumeur du patient. Dans chaque cas, les cellules tumorales sont utilisées comme point de départ dans l'hypothèse que seules les cellules tumorales contiendront une quantité importante d'antigènes spécifiques de tumeur ou d'antigènes associés et les origines tissulaires des cellules correspondent à l'emplacement de la tumeur du patient. Un premier aspect de l'invention est l'utilisation de cellules immortalisées, normales et non malignes à la base d'un vaccin allogénique contre le cancer basé sur un traitement cellulaire. Les cellules normales ne présentent pas d'antigènes spécifiques de tumeur ou des concentrations importantes d'antigènes associés, il est donc surprenant que des cellules normales soient efficaces en tant que vaccins contre le cancer. Pour le cancer de la prostate, par exemple, on pourrait mettre au point un vaccin à base d'une ou d'une combinaison de plusieurs lignées cellulaires normales immortalisées issues de la prostate. Avant toute utilisation chez les mammifères ou les humains, les lignées cellulaires sont mortellement irradiées aux rayons gamma à 50-300 Gy pour s'assurer qu'elles ne pourront plus se répliquer.
PCT/GB1999/004129 1998-12-10 1999-12-09 Nouveaux traitements contre le cancer WO2000033869A2 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IL14329699A IL143296A0 (en) 1998-12-10 1999-12-09 Use of human prostate cell lines in cancer treatment
AT99959542T ATE304365T1 (de) 1998-12-10 1999-12-09 Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs
DE69927286T DE69927286T2 (de) 1998-12-10 1999-12-09 Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs
EP99959542A EP1137422B1 (fr) 1998-12-10 1999-12-09 Utilisation de lignees cellulaires humaines de la prostate pour traiter le cancer de la prostate
AU16683/00A AU763485B2 (en) 1998-12-10 1999-12-09 New cancer treatments
US09/857,691 US6972128B1 (en) 1998-12-10 1999-12-09 Use of human prostrate cell lines in prostate cancer treatment
NZ512004A NZ512004A (en) 1998-12-10 1999-12-09 Immunotherapeutic agent for the treatment of prostate cancer comprising 3 prostate cell lines one derived from normal tissue and two from tumor tissue
JP2000586359A JP4949554B2 (ja) 1998-12-10 1999-12-09 ガンの新規処置
HU0104568A HUP0104568A3 (en) 1998-12-10 1999-12-09 Human prostatic cell lines for cancer treatment
MXPA01005816A MXPA01005816A (es) 1998-12-10 1999-12-09 Uso de lineas de celula de prostata humana en el tratamiento de cancer.
KR1020017007096A KR20010090874A (ko) 1998-12-10 1999-12-09 인간 전립선 세포계를 사용한 암치료법
CA2354045A CA2354045C (fr) 1998-12-10 1999-12-09 Nouveaux traitements contre le cancer
IL143296A IL143296A (en) 1998-12-10 2001-05-22 Factor containing a line of prostate cells, preparations containing it and use in the treatment of prostate cancer
NO20012634A NO327044B1 (no) 1998-12-10 2001-05-29 Allogent immunterapeutisk middel, immunogen sammensetning, vaksinesammensetning og anvendelser derav, i forbindelse med behandling av prostatakreft
US11/178,415 US8034360B2 (en) 1998-12-10 2005-07-12 Use of human prostate cell lines in cancer treatment
US13/270,820 US20120164099A1 (en) 1998-12-10 2011-10-11 Use of human prostate cell lines in cancer treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments
GB9827104.2 1998-12-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09857691 A-371-Of-International 1999-12-09
US11/178,415 Continuation US8034360B2 (en) 1998-12-10 2005-07-12 Use of human prostate cell lines in cancer treatment

Publications (2)

Publication Number Publication Date
WO2000033869A2 WO2000033869A2 (fr) 2000-06-15
WO2000033869A3 true WO2000033869A3 (fr) 2000-10-12

Family

ID=10843926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/004129 WO2000033869A2 (fr) 1998-12-10 1999-12-09 Nouveaux traitements contre le cancer

Country Status (19)

Country Link
US (3) US6972128B1 (fr)
EP (1) EP1137422B1 (fr)
JP (2) JP4949554B2 (fr)
KR (1) KR20010090874A (fr)
AT (1) ATE304365T1 (fr)
AU (1) AU763485B2 (fr)
CA (1) CA2354045C (fr)
CZ (1) CZ300499B6 (fr)
DE (1) DE69927286T2 (fr)
ES (1) ES2249046T3 (fr)
GB (1) GB9827104D0 (fr)
HU (1) HUP0104568A3 (fr)
IL (2) IL143296A0 (fr)
MX (1) MXPA01005816A (fr)
NO (1) NO327044B1 (fr)
NZ (1) NZ512004A (fr)
PL (1) PL201016B1 (fr)
WO (1) WO2000033869A2 (fr)
ZA (1) ZA200104164B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
WO2000071156A2 (fr) * 1999-05-21 2000-11-30 Onyvax Limited Nouvelles formulations vaccinales-3
US7303911B2 (en) * 2000-04-01 2007-12-04 Onyvax Limited Prostate cell lines
US6667479B2 (en) * 2001-06-01 2003-12-23 Raytheon Company Advanced high speed, multi-level uncooled bolometer and method for fabricating same
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
CA2536669A1 (fr) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Procedes d'administration intradermique d'agents therapeutiques
WO2008096831A1 (fr) * 2007-02-07 2008-08-14 The Research Foundation For Microbial Diseases Of Osaka University Agent thérapeutique contre le cancer
JPWO2009066462A1 (ja) * 2007-11-20 2011-04-07 日本電気株式会社 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
AU2009200767A1 (en) * 2008-03-10 2009-09-24 Aristocrat Technologies Australia Pty Limited A gaming system and a method of gaming
WO2010057197A1 (fr) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Compositions de vaccins contre le cancer et leurs méthodes d’utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028255A1 (fr) * 1996-02-02 1997-08-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Lignees de cellules epitheliales immortalisees provenant de prostate d'origine humaine, clones correspondants et leurs applications s'agissant de recherche et de therapie du cancer de la prostate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2120503C (fr) * 1991-10-04 2006-04-04 Glenn Dranoff Regulation des reactions immunitaires systemiques a l'aide de cytokines et d'antigenes
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
WO1995029704A1 (fr) * 1994-04-28 1995-11-09 Scott Freeman Lignees cellulaires obtenues par migration in vivo et par fusion avec des cellules autoimmune
DE69636514D1 (de) * 1995-03-17 2006-10-19 Univ California Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
DE69627527T2 (de) * 1995-12-28 2004-03-04 The Johns Hopkins University School Of Medicine Allogene parakrine cytokine tumor impfstoffe
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028255A1 (fr) * 1996-02-02 1997-08-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Lignees de cellules epitheliales immortalisees provenant de prostate d'origine humaine, clones correspondants et leurs applications s'agissant de recherche et de therapie du cancer de la prostate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABLIN R J: "A retrospective and prospective overview of prostate-specific antigen.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, (1997). VOL. 123, NO. 11-12, PP. 583-94. JOURNAL CODE: HL5. ISSN: 0171-5216., Innapharma Inc., Upper Saddle River, NJ 07458-1935, USA., XP000915510 *
TJOA, BENJAMIN (1) ET AL: "In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy.", PROSTATE, (1995) VOL. 27, NO. 2, PP. 63-69., XP000915509 *
VIEWEG J ET AL: "Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.", CANCER RESEARCH, (1994 APR 1) 54 (7) 1760-5., XP002140267 *

Also Published As

Publication number Publication date
MXPA01005816A (es) 2002-03-27
AU763485B2 (en) 2003-07-24
NO20012634L (no) 2001-08-08
HUP0104568A3 (en) 2004-05-28
JP2002531520A (ja) 2002-09-24
DE69927286T2 (de) 2006-06-29
PL201016B1 (pl) 2009-02-27
KR20010090874A (ko) 2001-10-19
EP1137422A2 (fr) 2001-10-04
WO2000033869A2 (fr) 2000-06-15
GB9827104D0 (en) 1999-02-03
PL348828A1 (en) 2002-06-17
ATE304365T1 (de) 2005-09-15
US20120164099A1 (en) 2012-06-28
JP2012021028A (ja) 2012-02-02
AU1668300A (en) 2000-06-26
US6972128B1 (en) 2005-12-06
ES2249046T3 (es) 2006-03-16
DE69927286D1 (de) 2005-10-20
CA2354045A1 (fr) 2000-06-15
IL143296A0 (en) 2002-04-21
NO327044B1 (no) 2009-04-06
NO20012634D0 (no) 2001-05-29
HUP0104568A2 (hu) 2002-03-28
IL143296A (en) 2006-06-11
CZ20012032A3 (cs) 2001-10-17
US20050249756A1 (en) 2005-11-10
NZ512004A (en) 2003-08-29
JP4949554B2 (ja) 2012-06-13
CA2354045C (fr) 2012-02-21
CZ300499B6 (cs) 2009-06-03
EP1137422B1 (fr) 2005-09-14
US8034360B2 (en) 2011-10-11
ZA200104164B (en) 2002-01-24

Similar Documents

Publication Publication Date Title
Staberg et al. The carcinogenic effect of UVA irradiation
Morton et al. Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus
Marks et al. Trends in non‐melanocytic skin cancer treated in Australia: the second national survey
WO2000033869A3 (fr) Nouveaux traitements contre le cancer
PL348829A1 (en) New cancer treatments
CN106176259B (zh) 一种具有双重隔离和晒后修复作用的防晒霜
CN105616280B (zh) 一种舒缓抗敏修护冰粒水
Rosenstein et al. p53 mutations in basal cell carcinomas arising in routine users of sunscreens
Conley Cancer of the skin of the nose
CN108014060B (zh) 一种防晒增效组合物及其应用
IL114382A0 (en) Cancer therapy using lymphotoxin
GB2419530A (en) Human prostate cell lines in cancer treatment
Chor et al. Successful treatment of oral lesions of chronic lichenoid graft‐vs.‐host disease by the addition of low‐level laser therapy to systemic immunosuppression
JPH08337510A (ja) メラニン生成抑制剤
ATE375163T1 (de) Zusammensetzungen enthaltend vernix und ein uv- schutzmittel, und deren verwendung
Finkel Sorting the hype from the facts in melanoma
WO2000033871A3 (fr) Nouveaux traitements du cancer
Woolley et al. A young military pilot presents with a periocular Basal Cell Carcinoma: A case report
CN102068397A (zh) 多功能防晒霜
CN104983627A (zh) 一种天然植物防晒护肤霜
Mapurisa et al. Case Report: Locally advanced skin cancer in an albino, a treatment dilemma
Cahn et al. Normal Skin Reactions to Ultraviolet Light: 1. An Attempt to Modify Normal Erythema and Pigmentation with Methoxsalen
Arsovska et al. International Journal of Current Advan
SALMANPOOR et al. EFFICACY OF EXCISIONAL SURGERY, CURETTAGE AND COMBINED CURETTAGE AND ELECTRODESSICATION IN TREATMENT OF BASAL CELL CARCINOMA (LETTER TO EDITOR)
Affleck Sun exposure and health.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2000 16683

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 143296

Country of ref document: IL

Ref document number: 2001/04164

Country of ref document: ZA

Ref document number: 200104164

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 512004

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 16683/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2354045

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2354045

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2001-2032

Country of ref document: CZ

Ref document number: 1020017007096

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 586359

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Country of ref document: MX

Ref document number: PA/a/2001/005816

Ref document number: 1999959542

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09857691

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999959542

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-2032

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017007096

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 16683/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999959542

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017007096

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载